Accurate coding for history of prostate cancer is essential for clinical clarity, compliance, and appropriate reimbursement. A documented history of prostate cancer affects follow-up care decisions, surveillance protocols (including PSA testing and imaging), risk stratification for new symptoms, and quality reporting. For revenue cycle management, correct diagnosis sequencing prevents claim denials, supports medical necessity, and reduces audit exposure.
This guide explains when to use the ICD-10 code for Personal history of malignant neoplasm of prostate, provides concrete clinical scenarios, highlights common coding pitfalls, lists closely related codes, and offers practical billing and documentation best practices to improve first-pass acceptance and audit readiness.
The ICD-10-CM Code for Personal history of malignant neoplasm of prostate is Z85.46.
Personal history of malignant neoplasm of prostate describes a patient who previously had a diagnosed malignant tumor of the prostate that has been treated, resolved, or is no longer considered active malignancy for the purposes of coding. This code does not indicate current active cancer treatment or evidence of residual disease; rather it documents past malignancy as part of the patient's medical history. In the ICD-10-CM classification, Z85.46 is a V-code-equivalent category used to capture the completed episode of care for prostate cancer, to inform clinicians and payers about prior oncologic history that may affect current care.
Use Personal history of malignant neoplasm of prostate when a patient presents for routine primary care and the record documents a prior diagnosis of prostate cancer that was definitively treated (for example, prostatectomy, radiation therapy, or documented remission) with no current evidence of active disease. This code supports preventive care decisions and longitudinal problem lists.
Use this code when a patient with a prior prostate cancer diagnosis comes for surveillance testing (PSA monitoring, digital rectal exam) and the visit is coded to reflect history rather than active malignancy. Z85.46 indicates the reason surveillance is being performed and supports medical necessity for monitoring services when documented.
Use Personal history of malignant neoplasm of prostate for preoperative evaluations when prior prostate cancer influences perioperative risk assessment, decision-making, or consent. This clarifies the history without implying active cancer treatment is occurring.
Use Z85.46 on problem lists and encounter diagnoses when past prostate cancer impacts current management (e.g., considerations for androgen deprivation therapy side effects, bone health monitoring, or cardiovascular risk stratification) but there is no current active neoplasm.
Do not use Personal history of malignant neoplasm of prostate if chart indicates active disease, ongoing chemotherapy, radiation, or active surveillance with evidence of cancer persistence. Instead code the active malignant neoplasm of prostate (C61) and any treatment codes that reflect current management.
Do not use Z85.46 to report complications (for example, urinary incontinence due to prostatectomy) or documented recurrence; use codes that identify the complication or recurrent malignant neoplasm (code C79.82 for secondary malignant neoplasm of prostate if metastasis, or appropriate complication codes) depending on documentation.
Do not use Personal history of malignant neoplasm of prostate when the patient has an elevated PSA, hematuria, or urinary symptoms without documentation of a prior prostate cancer diagnosis. Use symptom or abnormal test result codes (for example, R97.2 for elevated PSA) until history is confirmed.
Do not use Z85.46 if the patient’s prior cancer was at a different site (e.g., bladder, testis). Use the specific personal history code that corresponds to the documented previous malignancy (for example, Z85.51 for bladder) to maintain clinical accuracy.
ConditionCodeWhen It Is UsedWhen It Is Not UsedPersonal history of malignant neoplasm of prostateZ85.46Use when prior prostate cancer was treated and there is no evidence of active malignancy; documents past cancer for surveillance, risk stratification, or comorbidity coding.Not used when active prostate cancer, recurrence, metastasis, or treatment-related complications are documented; use active malignancy codes (C61) or complication/recurrence codes instead.Malignant neoplasm of prostateC61Use when prostate cancer is active, being treated, or confirmed on current diagnostic workup; bill when treatment, chemotherapy, radiation, or tumor-directed procedures are performed.Not used when cancer is in complete remission or when only history of prior prostate cancer is documented without evidence of active disease; use Z85.46 in those cases.Encounter for follow-up examination after completed treatment of malignant neoplasmZ08Use when the visit specifically documents follow-up examinations after completed cancer treatment and the focus is surveillance exams tied to prior malignancy.Not used as the sole code when active disease, recurrence, or ongoing treatment is present; pair with site-specific codes for clarity when required.Elevated prostate specific antigen (PSA)R97.2Use when PSA is elevated or abnormal and there is no documented prior or active prostate cancer diagnosis; supports diagnostic workup for possible malignancy.Not used to represent past treated prostate cancer; do not use when the reason for visit is surveillance because of known prior prostate cancer—use Z85.46 plus any symptom codes as appropriate.
Always document whether prostate cancer is active, in remission, treated, or recurrent. Clear status supports correct selection of Z85.46 versus active disease codes and reduces denials for medical necessity.
When ordering surveillance tests or imaging because of prior prostate cancer, document the clinical rationale (e.g., "surveillance PSA q6 months after prostatectomy for prior prostate cancer") to substantiate medical necessity for payers.
Place the encounter’s primary reason in the first position and include Z85.46 as a secondary diagnosis when the history impacts care. For surveillance visits where history drives testing, code sequencing should reflect that to justify ordered services.
Ensure CPT/HCPCS codes for PSA testing, biopsy, imaging, or procedural care correspond to the documented surveillance or treatment plan. Incorrect procedure-code pairings with Z85.46 increase audit risk.
Use automated coding validation to flag conflicts (e.g., Z85.46 listed with active cancer treatment codes) and to check for missing linkage between history and ordered services. CombineHealth.ai's AI-powered platform and automated claim scrubbing can reduce mismatches that drive denials.
Coding for history of prostate cancer has direct impact on revenue cycle outcomes:
Accurate ICD-10 coding is critical for healthcare revenue cycle performance. CombineHealth.ai's AI-powered platform helps RCM teams ensure coding accuracy, reduce denials, and optimize reimbursement through intelligent denial management and claim validation. CombineHealth.ai's intelligent platform provides automated claim scrubbing and coding validation to catch errors before submission, reducing denials and improving first-pass acceptance rates.
The ICD-10-CM code for history of prostate cancer is Z85.46. Use this code when the chart documents a prior malignant neoplasm of the prostate that has been treated or is not currently active, and the visit concerns surveillance, risk assessment, or documentation of past cancer.
Use Personal history of malignant neoplasm of prostate (Z85.46) for resolved, treated, or inactive prostate cancer. Use C61 when cancer is active or being treated. Use Z08 for visits explicitly coded as follow-up exams after completed cancer treatment when documentation supports that designation. Use R97.2 for isolated elevated PSA without a documented prior prostate cancer diagnosis.
Document the original diagnosis, dates and types of definitive treatment, current disease status (remission, resolved, or recurrence), and the clinical reason for current services. For surveillance testing, document the monitoring interval and rationale tied to the prior prostate cancer.
Common denials stem from using Z85.46 when active treatment is documented, failing to link surveillance tests to the prior malignancy, missing evidence of prior cancer in the record, and conflicting procedure codes that suggest active disease. See our guide on denial management for strategies to reduce denials and improve claims performance.